|
HALIFAX, Dec. 16 /PRNewswire-FirstCall/ - MedMira Inc. ("MedMira") (TSX
Venture: MIR, NASDAQ:MMIRF) the global market leader in premium rapid
diagnostic solutions, today announced that it will host a conference call with
analysts to discuss the companys first quarter financial results beginning at
9:00 a.m. Eastern Standard Time (10:00 a.m. Atlantic) on Tuesday, December 20,
2005. The call will be preceded by the release of the companys first quarter
financial results the previous evening and they will be available on the
MedMira web site http://www.medmira.com
In order to listen to the conference call, please either dial
800-814-4862 for toll-free anywhere in Canada or the USA, or 416-644-3423 in
the Toronto area.
A replay of the call will be available until 23:59 EST Tuesday, December
27, 2005 and may be accessed by dialing 877-289-8525 for toll-free anywhere in
Canada or the USA, or 416-640-1917 in the Toronto area and entering the pass
code: 21168765 followed by the number sign anytime after the call has been
ended.
About MedMira
MedMira is the leading global manufacturer and marketer of in vitro flow-
through rapid diagnostic tests. MedMiras tests provide reliable, rapid
diagnosis in just 3 minutes for the detection of human antibodies in human
serum, plasma or whole blood for diseases such as HIV and hepatitis C. The
United States FDA and the SFDA in the Peoples Republic of China have approved
MedMiras Reveal(R) G2 and MiraWell(R) rapid HIV tests, respectively.
MedMiras Reveal(R) G2 and MiraWell(R) rapid HIV tests are currently used
in clinical laboratories, hospitals, and clinics where professional
counselling and patient treatment are immediately available.
The MiraCare(TM) Rapid HIV Antibody Test, MedMiras over-the-counter
(OTC) product, is available in pharmacies throughout Hong Kong and Macao
Special Administrative Regions, in the Peoples Republic of China.
MedMira delivers rapid diagnostic solutions to healthcare communities
around the globe. Its corporate offices and manufacturing facilities are
located in Halifax, Nova Scotia, Canada with a representative office in
Guilin, China.
This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the companys current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
For more information visit MedMiras website at http://www.medmira.com.
|
|
